S. Y. Zhang, M. Herman, M. J. Ciancanelli, R. Perez-de-diego, V. Sancho-shimizu et al., TLR3 immunity to infection in mice and humans, vol.25, pp.19-33, 2013.

E. Vacchelli, A. Eggermont, C. Sautes-fridman, J. Galon, L. Zitvogel et al., Trial Watch: Toll-like receptor agonists for cancer therapy, OncoImmunology, vol.2, p.25238, 2013.

S. Rakoff-nahoum and R. Medzhitov, Toll-like receptors and cancer, Nat. Rev. Cancer, vol.9, pp.57-63, 2009.

B. Salaun, I. Coste, M. C. Rissoan, S. J. Lebecque, and T. Renno, TLR3 can directly trigger apoptosis in human cancer cells, J. Immunol, vol.176, pp.4894-4901, 2006.

T. Morikawa, A. Sugiyama, H. Kume, S. Ota, T. Kashima et al., Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma, Clin. Cancer Res, vol.13, pp.5703-5709, 2007.

C. Rydberg, A. Mansson, R. Uddman, K. Riesbeck, and L. O. Cardell, Toll-like receptor agonists induce inflammation and cell death in a model of head and neck squamous cell carcinomas, Immunology, vol.128, pp.600-611, 2009.

B. Verillaud, M. Gressette, Y. Morel, C. Paturel, P. Herman et al., Toll-like receptor 3 in Epstein-Barr virus-associated nasopharyngeal carcinomas: consistent expression and cytotoxic effects of its synthetic ligand poly(A:U) combined to a Smac-mimetic, Infect. Agents Cancer, vol.7, p.36, 2012.

A. Paone, D. Starace, R. Galli, F. Padula, P. De-cesaris et al., Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism, Carcinogenesis, vol.29, pp.1334-1342, 2008.

D. Chiron, C. Pellat-deceunynck, M. Amiot, R. Bataille, and G. Jego, TLR3 ligand induces NF-{kappa}B activation and various fates of multiple myeloma cells depending on IFN-{alpha} production, J. Immunol, vol.182, pp.4471-4478, 2009.

Y. Estornes, F. Toscano, F. Virard, G. Jacquemin, A. Pierrot et al., dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8, Cell Death Differ, vol.19, pp.1482-1494, 2012.

L. Alkurdi, F. Virard, B. Vanbervliet, K. Weber, F. Toscano et al., Release of c-FLIP brake selectively sensitizes human cancer cells to TLR3-mediated apoptosis, Cell Death Dis, vol.9, p.874, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01871291

M. Feoktistova, P. Geserick, B. Kellert, D. P. Dimitrova, C. Langlais et al., Leverkus, cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms, Mol. Cell, vol.43, pp.449-463, 2011.

P. Chirac, D. Maillet, F. Lepretre, S. Isaac, O. Glehen et al., Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array, Hum. Pathol, vol.55, pp.72-82, 2016.

N. Leblay, F. Lepretre, N. L. Stang, A. Gautier-stein, L. Villeneuve et al., BAP1 is altered by copy number loss, mutation, and/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas, J. Thorac. Oncol, vol.12, pp.724-733, 2017.

A. Scherpereel, F. Wallyn, S. M. Albelda, and C. Munck, Novel therapies for malignant pleural mesothelioma, Lancet Oncol, vol.19, pp.161-172, 2018.

A. Scherpereel, J. Mazieres, L. Greillier, S. Lantuejoul, P. Do et al., French Cooperative Thoracic I. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial, Lancet Oncol, vol.20, pp.239-253, 2019.

V. Kepenekian, D. Elias, G. Passot, E. Mery, D. Goere et al., French Network for Rare Peritoneal, Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: multi-Institutional Retrospective Study, Eur. J. Cancer, vol.65, pp.69-79, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01368938

C. Combaz-lair, F. Galateau-salle, A. Mcleer-florin, N. L. Stang, L. David-boudet et al., Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas, vol.52, pp.9-18, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01792622

F. Gueugnon, S. Leclercq, C. Blanquart, C. Sagan, L. Cellerin et al., Identification of novel markers for the diagnosis of malignant pleural mesothelioma, Am. J. Pathol, vol.178, pp.1033-1042, 2011.

F. Toscano, Y. Estornes, F. Virard, A. Garcia-cattaneo, A. Pierrot et al., Cleaved/associated TLR3 represents the primary form of the signaling receptor, J. Immunol, vol.190, pp.764-773, 2013.

M. Matsumoto, Y. Takeda, M. Tatematsu, and T. Seya, Toll-like receptor 3 signal in dendritic cells benefits cancer immunotherapy, Front. Immunol, vol.8, p.1897, 2017.

L. Alexopoulou, A. C. Holt, R. Medzhitov, and R. A. Flavell, Recognition of doublestranded RNA and activation of NF-kappaB by Toll-like receptor 3, Nature, vol.413, pp.732-738, 2001.

H. Kato, O. Takeuchi, S. Sato, M. Yoneyama, M. Yamamoto et al., Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses, Nature, vol.441, pp.101-105, 2006.

H. Wang, L. Sun, L. Su, J. Rizo, L. Liu et al., Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3, Mol. Cell, vol.54, pp.133-146, 2014.

M. R. Abedini, E. J. Muller, J. Brun, R. Bergeron, D. A. Gray et al., Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells, Cancer Res, vol.68, pp.4511-4517, 2008.

J. H. Song, D. K. Song, M. Herlyn, K. C. Petruk, and C. Hao, Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells, Clin. Cancer Res, vol.9, pp.4255-4266, 2003.

H. Kinoshita, H. Yoshikawa, K. Shiiki, Y. Hamada, Y. Nakajima et al., Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating FLIP-L expression, Int. J. Cancer, vol.88, pp.986-991, 2000.

E. Varfolomeev, J. W. Blankenship, S. M. Wayson, A. V. Fedorova, N. Kayagaki et al., IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis, Cell, vol.131, pp.669-681, 2007.

H. Li, H. Zhu, C. J. Xu, and J. Yuan, Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis, Cell, vol.94, pp.491-501, 1998.

M. Shatz, D. Menendez, and M. A. Resnick, The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells, Cancer Res, vol.72, pp.3948-3957, 2012.

O. Micheau, E. Solary, A. Hammann, F. Martin, and M. T. Dimanche-boitrel, Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity, J. Natl. Cancer Inst, vol.89, pp.783-789, 1997.

M. Nagane, G. Pan, J. J. Weddle, V. M. Dixit, W. K. Cavenee et al., Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo, Cancer Res, vol.60, pp.847-853, 2000.

K. Kondo, S. Yamasaki, T. Sugie, N. Teratani, T. Kan et al., Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma, Int. J. Cancer, vol.118, pp.230-242, 2006.

L. Galligan, D. B. Longley, M. Mcewan, T. R. Wilson, K. Mclaughlin et al., Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP, Mol. Cancer Ther, vol.4, pp.2026-2036, 2005.

A. Weber, Z. Kirejczyk, R. Besch, S. Potthoff, M. Leverkus et al., Proapoptotic signalling through Toll-like receptor-3 involves TRIF-dependent activation of caspase-8 and is under the control of inhibitor of apoptosis proteins in melanoma cells, Cell Death Differ, vol.17, pp.942-951, 2010.

N. Yatim, S. Cullen, and M. L. Albert, Dying cells actively regulate adaptive immune responses, Nat. Rev. Immunol, vol.17, pp.262-275, 2017.
URL : https://hal.archives-ouvertes.fr/pasteur-01491773

D. V. Krysko, K. D'herde, and P. Vandenabeele, Clearance of apoptotic and necrotic cells and its immunological consequences, Apoptosis, vol.11, pp.1709-1726, 2006.

N. Yatim, H. Jusforgues-saklani, S. Orozco, O. Schulz, R. Barreira-da-silva et al., RIPK1 and NF-kappaB signaling in dying cells determines cross-priming of CD8(+) T cells, Science, vol.350, pp.328-334, 2015.

Z. H. Siddik, Cisplatin: mode of cytotoxic action and molecular basis of resistance, Oncogene, vol.22, pp.7265-7279, 2003.

O. Micheau, E. Solary, A. Hammann, and M. T. , Dimanche-Boitrel, Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs, J. Biol. Chem, vol.274, pp.7987-7992, 1999.

C. G. Ferreira, C. Tolis, S. W. Span, G. J. Peters, T. Van-lopik et al., Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway, Clin. Cancer Res, vol.6, pp.203-212, 2000.

L. Ding, J. Ren, D. Zhang, Y. Li, X. Huang et al., The TLR3 agonist inhibit drug efflux and sequentially consolidates low-dose cisplatinbased chemoimmunotherapy while reducing side effects, Mol. Cancer Ther, vol.16, pp.1068-1079, 2017.

M. Mikulandra, A. Kobescak, B. Verillaud, P. Busson, and T. Matijevic-glavan, Radiosensitization of head and neck cancer cells by a combination of poly(I:C) and cisplatin through downregulation of survivin and c-IAP2, Cell. Oncol, vol.42, pp.29-40, 2019.

M. Matsumoto, M. Tatematsu, F. Nishikawa, M. Azuma, N. Ishii et al., Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo, Nat. Commun, vol.6, p.6280, 2015.

K. Naumann, R. Wehner, A. Schwarze, C. Petzold, M. Schmitz et al., Activation of dendritic cells by the novel Toll-like receptor 3 agonist RGC100, Clin. Dev. Immunol, vol.2013, p.283649, 2013.